Terms: = Gastric cancer AND KDR, VEGFR2, 3791, ENSG00000128052, P35968, VEGFR, CD309, FLK1 AND Treatment
186 results:
1. First-line camrelizumab (a PD-1 inhibitor) plus apatinib (an vegfr-2 inhibitor) and chemotherapy for advanced gastric cancer (SPACE): a phase 1 study.
Chen X; Xu H; Chen X; Xu T; Tian Y; Wang D; Guo F; Wang K; Jin G; Li X; Wang R; Li F; Ding Y; Tang J; Fang Y; Zhao J; Liu L; Ma L; Meng L; Hou Z; Zheng R; Liu Y; Guan N; Zhang B; Tong S; Chen S; Li X; Shu Y
Signal Transduct Target Ther; 2024 Mar; 9(1):73. PubMed ID: 38528050
[TBL] [Abstract] [Full Text] [Related]
2. The pathological roles and potential mechanisms of vascular endothelial growth factor receptor-3 in gastric cancer.
Li XF; Zhang XJ; Hao FR; Dong XT; Xu GD; Zhang YX
J Int Med Res; 2024 Mar; 52(3):3000605241234558. PubMed ID: 38518198
[TBL] [Abstract] [Full Text] [Related]
3. Efficacy of ramucirumab combination chemotherapy as second-line treatment in patients with advanced adenocarcinoma of the stomach or gastroesophageal junction after exposure to checkpoint inhibitors and chemotherapy as first-line therapy.
Masetti M; Al-Batran SE; Goetze TO; Thuss-Patience P; Knorrenschild JR; Goekkurt E; Folprecht G; Ettrich TJ; Lindig U; Luley KB; Pink D; Dechow T; Sookthai D; Junge S; Loose M; Pauligk C; Lorenzen S
Int J Cancer; 2024 Jun; 154(12):2142-2150. PubMed ID: 38447003
[TBL] [Abstract] [Full Text] [Related]
4. Advances in targeted therapy for gastric cancer based on tumor driver genes.
Wu S; Xu P; Zhang F
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2023 Feb; 53(1):73-83. PubMed ID: 38413217
[TBL] [Abstract] [Full Text] [Related]
5. Regulation of regulatory T cells and tumor-associated macrophages in gastric cancer tumor microenvironment.
Shaopeng Z; Yang Z; Yuan F; Chen H; Zhengjun Q
Cancer Med; 2024 Jan; 13(2):e6959. PubMed ID: 38349050
[TBL] [Abstract] [Full Text] [Related]
6. PD-1 inhibitor combined with albumin paclitaxel and apatinib as second-line treatment for patients with metastatic gastric cancer: a single-center, single-arm, phase II study.
Gou M; Zhang Y; Wang Z; Qian N; Dai G
Invest New Drugs; 2024 Apr; 42(2):171-178. PubMed ID: 38347177
[TBL] [Abstract] [Full Text] [Related]
7. Rivoceranib, a vegfr-2 inhibitor, monotherapy in previously treated patients with advanced or metastatic gastric or gastroesophageal junction cancer (ANGEL study): an international, randomized, placebo-controlled, phase 3 trial.
Kang YK; Ryu MH; Di Bartolomeo M; Chau I; Yoon H; Kim JG; Lee KW; Oh SC; Takashima A; Kryzhanivska A; Chao Y; Evesque L; Schenker M; McGinn A; Zhao Y; Lee J; Wyrwicz L; Boku N
Gastric Cancer; 2024 Mar; 27(2):375-386. PubMed ID: 38281295
[TBL] [Abstract] [Full Text] [Related]
8. Clinical Management of gastric cancer treatment Regimens.
Boilève J; Touchefeu Y; Matysiak-Budnik T
Curr Top Microbiol Immunol; 2023; 444():279-304. PubMed ID: 38231223
[TBL] [Abstract] [Full Text] [Related]
9. gastric tubular adenocarcinoma with diffuse neutrophils infiltrating: characteristics and probable treatment strategy.
Wang B; Zhu Y; Wang S; Li Z; Wang L; Rao W; Cheng N; Chen R; Ying J; Xue L
Gastric Cancer; 2024 Jan; 27(1):86-101. PubMed ID: 38019350
[TBL] [Abstract] [Full Text] [Related]
10. PDGFRβ Signaling Cooperates with β-Catenin to Modulate c-Abl and Biologic Behavior of Desmoid-Type Fibromatosis.
Hu J; Hameed MR; Agaram NP; Whiting KA; Qin LX; Villano AM; O'Connor RB; Rozenberg JM; Cohen S; Prendergast K; Kryeziu S; White RL; Posner MC; Socci ND; Gounder MM; Singer S; Crago AM
Clin Cancer Res; 2024 Jan; 30(2):450-461. PubMed ID: 37943631
[TBL] [Abstract] [Full Text] [Related]
11. Comprehensive exploration of Biochanin A as an oncotherapeutics potential in the treatment of multivarious cancers with molecular insights.
Sohel M
Phytother Res; 2024 Feb; 38(2):489-506. PubMed ID: 37905329
[TBL] [Abstract] [Full Text] [Related]
12. [Skip metastasis at the esophageal resection margin in radical gastrectomy: clinical characteristics of 30 cases].
Liu S; Xia QY; Fu Y; Lu XF; Wang M; Guan WX
Zhonghua Wei Chang Wai Ke Za Zhi; 2023 Jul; 26(7):675-679. PubMed ID: 37583025
[No Abstract] [Full Text] [Related]
13. The multifaceted mechanisms of ellagic acid in the treatment of tumors: State-of-the-art.
Lu G; Wang X; Cheng M; Wang S; Ma K
Biomed Pharmacother; 2023 Sep; 165():115132. PubMed ID: 37423169
[TBL] [Abstract] [Full Text] [Related]
14. Anthracycline chemicals with anthracyclinone structure exert antitumor effects by inhibiting angiogenesis and lymphangiogenesis in a xenografted gastric tumor model.
Li H; Jia C; Li C; Wang Y; Du W; Jiang H
Gastric Cancer; 2023 Nov; 26(6):863-877. PubMed ID: 37344705
[TBL] [Abstract] [Full Text] [Related]
15. Safety and efficacy of apatinib in patients with advanced gastric or gastroesophageal junction adenocarcinoma after the failure of two or more lines of chemotherapy (AHEAD): a prospective, single-arm, multicenter, phase IV study.
Li J; Qin S; Wen L; Wang J; Deng W; Guo W; Jia T; Jiang D; Zhang G; He Y; Ba Y; Zhong H; Wang L; Lin X; Yang J; Zhao J; Bai Y; Wu X; Gao F; Sun G; Wu Y; Ye F; Wang Q; Xie Z; Yi T; Huang Y; Yu G; Lu L; Yuan Y; Li W; Liu L; Sun Y; Sun Y; Yin L; Hou Z
BMC Med; 2023 May; 21(1):173. PubMed ID: 37147645
[TBL] [Abstract] [Full Text] [Related]
16. An emphasis on the interaction of signaling pathways highlights the role of miRNAs in the etiology and treatment resistance of gastric cancer.
Fathi D; Elballal MS; Elesawy AE; Abulsoud AI; Elshafei A; Elsakka EGE; Ismail A; El-Mahdy HA; Elrebehy MA; Doghish AS
Life Sci; 2023 Jun; 322():121667. PubMed ID: 37023952
[TBL] [Abstract] [Full Text] [Related]
17. A Retrospective Cohort Study Examining the Effects of Anti-PD-1 Antibody in Combination with Apatinib in Patients Previously Treated for Her2-Negative Advanced gastric/Gastroesophageal Junction cancer.
Hou XF; Zhang XX; Li S; Wu C; Chen XB
J Clin Pharmacol; 2023 Jul; 63(7):769-775. PubMed ID: 37005358
[TBL] [Abstract] [Full Text] [Related]
18. A multicenter, phase Ib/II, open-label study of tivozanib with durvalumab in advanced hepatocellular carcinoma (DEDUCTIVE).
Mahmood S; Li D; Lee A; Rowe J; Beg M; Kasturi V; Iyer R; Abrams T; Dayyani F
Future Oncol; 2022 Dec; 18(40):4465-4471. PubMed ID: 36912078
[TBL] [Abstract] [Full Text] [Related]
19. Perioperative Tailored treatments for gastric cancer: Times Are Changing.
Lavacchi D; Fancelli S; Buttitta E; Vannini G; Guidolin A; Winchler C; Caliman E; Vannini A; Giommoni E; Brugia M; Cianchi F; Pillozzi S; Roviello G; Antonuzzo L
Int J Mol Sci; 2023 Mar; 24(5):. PubMed ID: 36902306
[TBL] [Abstract] [Full Text] [Related]
20. IMPACT OF TUMOR MOLECULAR PHENOTYPE ON SURVIVAL OF PATIENTS WITH gastric cancer AFTER RADICAL SURGERY.
Dumanskyi YV; Kirkilevskyi SI; Sulaeva OM; Polyasnyi VO; Mashukov AO; Kovalevska LA; Yarema RR; Ogorchak MA
Exp Oncol; 2022 Dec; 44(4):324-326. PubMed ID: 36811544
[TBL] [Abstract] [Full Text] [Related]
[Next]
